Organ Site Research最新文献

{"title":"Abstract A65: Evaluating an under-studied kinase as a potential druggable target for breast cancer","authors":"Hamzah A. Kharabsheh, Xiyou Zhou, John E. Scott","doi":"10.1158/1538-7755.DISP17-A65","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-A65","url":null,"abstract":"Breast cancer is the most frequently diagnosed cancer among women, accounting for 23% of all cancer cases. Triple-negative breast cancer (TNBC) is a very aggressive type of breast cancer that occurs in African-American women at three-fold higher frequency compared to Hispanic and Caucasian women. TNBC has a lower 5-year survival rate compared to other subtypes of breast cancer and no targeted therapeutics. In order to identify novel targets for TNBC, replicate kinome-wide RNAi screens were performed with HCC1806, a basal-like TNBC cell line, using a 4-day cell viability assay. Among the RNAi hits, we identified the COASY gene, encoding Coenzyme A synthase (CoAsy), as an under-studied kinase. Thus, we sought to confirm this RNAi hit and evaluate CoAsy for its potential as a novel druggable target for TNBC. CoAsy is a bifunctional enzyme that carries out the last two steps in the coenzyme A (CoA) biosynthetic pathway, including the phosphorylation of dephospho-CoA to generate CoA. Our hypothesis is that TNBC cells require a higher level of CoA synthase activity for cell proliferation compared to normal cells and thus inhibiting CoA synthase represents a novel therapeutic strategy for TNBC. Using four different individual RNAi targeting COASY, we used transient RNAi transfection of a panel of breast cancer cell lines and a non-transformed breast cell line to determine the effect of CoAsy knock down on cell viability and proliferation. Knockdown of CoAsy protein by RNAi was demonstrated by Western blot. Transient COASY RNAi transfection inhibited the cell viability/proliferation assay for several TNBC cell lines, but not for a normal breast cell line. Thus, these data suggest that knockdown of CoAsy may preferentially inhibit cell proliferation of breast cancer cell lines. In addition, Western blot was performed to determine and compare the expression of CoAsy in a panel of breast cancer cell lines and nontransformed cell lines. Ongoing studies are investigating the dependence of cell line viability and proliferation on the expression level of CoAsy by creating stable inducible shRNA cell lines. Citation Format: Hamzah Kharabsheh, Xiyou Zhou, John Scott. Evaluating an under-studied kinase as a potential druggable target for breast cancer [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr A65.","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123789209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PR03: Somatic mutations and ancestry markers in Hispanic lung cancer patients","authors":"W. Cress, Nicholas T. Gimbrone, Bhaswati Sarcar, E. Gordián, J. Rivera, C. López, J. Teer, E. Welsh, A. Chiappori, M. Schabath, G. Reuther, Pedro G Santiago-Cardona","doi":"10.1158/1538-7755.DISP17-PR03","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-PR03","url":null,"abstract":"Introduction: Hispanics are projected to constitute 23% of the U.S. population by 2050. However, large-scale sequencing projects, such as The Cancer Genome Atlas (TCGA), provide little information on this ethnic population. In fact, only seven out of over 500 lung adenocarcinoma tumors sequenced in the TCGA database are reported to be Hispanic. To address the lack of genomic data from Hispanic/Latino patients with lung cancer, the Latino Lung Cancer Registry was established to collect patient data and biospecimens from these patients. Methods: This retrospective observational study examined lung cancer tumor samples from 163 Hispanic/Latino patients, and tumor-derived DNA was subjected to targeted-exome sequencing (>1000 genes, including EGFR, KRAS, STK11, and TP53) and ancestry analysis. Mutation frequencies in this Hispanic/Latino cohort were compared with those in a similar cohort of non-Hispanic white (NHW) patients. Novel mutations in EGFR were functionally characterized, and mutation rates were correlated with ancestry, patient sex, smoking status, and tumor histology. Results: Among adenocarcinomas (n=120) in the Hispanic/Latino cohort, 31% had EGFR mutations versus 17% in the NHW control group (p Conclusions: Driver mutations in Hispanic/Latino lung adenocarcinoma patients differ in frequency from those in NHWs associated with their Indigenous American ancestry. The spectrum of driver mutations needs to be further assessed in the Hispanic/Latino population. Citation Format: William D. Cress, Nicholas T. Gimbrone, Bhaswati Sarcar, Edna Gordian, Jason I. Rivera, Christian Lopez, Jamie K. Teer, Eric A. Welsh, Alberto A. Chiappori, Matthew B. Schabath, Gary W. Reuther, Pedro G. Santiago-Cardona. Somatic mutations and ancestry markers in Hispanic lung cancer patients [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr PR03.","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"15 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120851247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PR02: β-Catenin overexpression underlies the aggressive disease course in African American triple-negative breast cancer patients who lack androgen receptor","authors":"Karuna Mittal, Shristi Bhattarai, S. Klimov, Uma Krishnamurthi, Xiaoxian Li, Ceyda Sonmez Wetherilt, Mohammad A. Aleskandaran, A. Green, E. Rakha, I. Ellis, G. Cantuaria, Guanhao Wei, Remus Osan, Meenakshi V. Gupta, U. Manne, P. Rida, R. Aneja","doi":"10.1158/1538-7755.DISP17-PR02","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-PR02","url":null,"abstract":"Background: Androgen receptor (AR) has emerged as a new target for treating TNBC. AR is expressed in 10-43% of TNBCs. Although there are conflicting reports in the literature about the effect of AR status on TNBC prognosis, agents targeting AR signaling (enzalutamide) are already being evaluated in AR-positive TNBCs in early-stage clinical trials. However, no study so far has evaluated the association/correlation of AR status with ethnicity in TNBCs and downstream effects of AR loss in TNBCs. Given the association of AR loss with poor prognosis in breast cancer and that the African American (AA) with TNBC suffers aggressive disease course when compared to European American (EA) TNBCs, we hypothesized that AR loss might be an underlying cause of aggressive disease course in AR-negative TNBCs. Thus, in this project we aimed to study if loss or gain of AR in AA and EA TNBCs regulates the expression of β-catenin and leads to more aggressive disease course by activating downstream canonical Wnt-beta catenin signaling. Methods: We evaluated AR expression immunohistochemically in 424 formalin-fixed, paraffin-embedded samples from TNBC patients for whom complete clinicopathologic and overall survival (OS) data were available. Samples with Results: IHC staining of AR indicated that 79.5% of AA TNBCs (n=214) and 70% of EA TNBCs (n=210) were AR negative. Loss of AR was associated with poor overall survival in adjuvant-treated high Ki67 (>14%) (HR=1.72; p=0.095) AA TNBC (n=98) when compared to EA TNBCs (n=80). These data were validated by our in silico findings, which suggested that EA TNBCs (n=81) exhibited higher levels of AR mRNA compared to AA TNBCs (n=41) (p Conclusion: This study suggests that increased expression of β-catenin coupled with AR loss in AAs may underlie the ethnic disparity in outcomes among TNBC patients and strongly supports the prognostic role of AR and β-catenin in this breast cancer subtype. Citation Format: Karuna Mittal, Shristi Bhattarai, Sergey Klimov, Uma Krishnamurthi, Xiaoxian Li, Ceyda Sonmez Wetherilt, Mohammad A. Aleskandaran, Andrew A. Green, Emad A. Rakha, Ian O. Ellis, Guilherme Cantuaria, Guanhao Wei, Remus Mihai Osan, Meenakshi V. Gupta, Upender Manne, Padmashree C.G Rida, Ritu Aneja. β-Catenin overexpression underlies the aggressive disease course in African American triple-negative breast cancer patients who lack androgen receptor [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr PR02.","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121570068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract B88: [Advocate Abstract:] An anthropological approach to African American prostate cancer disparity","authors":"G. Green","doi":"10.1158/1538-7755.DISP17-B88","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-B88","url":null,"abstract":"Originally, my poster board was only addressing my prostate cancer advocacy and disparity work that I do with the Men9s Health Committee/UCSF Helen Diller Family Comprehensive Cancer Center and Alameda County Office of Urban Male Health. And when the observer sees the Surveillance, Epidemiology, and End Results (SEER) data, the alarming national disparity patterns will become more apparent. To combat that trend, our prostate support group has developed a socialization pattern we call “Men Talk” to help men make more informed decisions. We9ll see if our local disparity decreases. If it does, then our model will become a candidate for national adoption. And since I9m engaged in other advocacy work, I decided to share those activities: 1. The Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN), where I9m involved with the Head and Neck Cancer Committee and the Cancer Research Advocates Committee 2. Kaiser Permanente Community Action Board (CAB), where I9m chair of the Northern California CAB Tissue Bank and member of Kaiser9s National CAB Tissue Bank 3. Sutter Health9s Ethnic Health Cancer Committee, where we focus on colon, breast, and prostate cancers I9ll provide more detail on all four (4) advocacy activities on the poster board and hopefully by sharing my other advocacy voices, the viewer gains a more complete picture of my advocacy interest and needs. Citation Format: Gerald Green. [Advocate Abstract:] An anthropological approach to African American prostate cancer disparity [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B88.","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"97 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131804753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A70: [Advocate Abstract:] We have breast too! A male breast cancer awareness program","authors":"W. Dornan","doi":"10.1158/1538-7755.DISP17-A70","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-A70","url":null,"abstract":"This poster will highlight a proposed male breast cancer educational program that will be carried out throughout Tennessee. Citation Format: Wayne Dornan. [Advocate Abstract:] We have breast too! A male breast cancer awareness program [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr A70.","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125847719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A83: Decreased nuclear expression of the E3 ubiquitin ligase Nrdp1 in African American men compared to Caucasian men with localized prostate cancer","authors":"Salma Siddiqui, Frank U. Melgoza, B. Durbin-Johnson, R. Vinall, P. Ghosh","doi":"10.1158/1538-7755.DISP17-A83","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-A83","url":null,"abstract":"Background: In the U.S., the incidence and mortality rates of prostate cancer (CaP) for African American (AA) men are about 1.5 and 2.3 times higher compared to Caucasian American (CA) men, respectively. CaP is diagnosed at an earlier age and is more aggressive in AA compared to CA patients. The causes for these differences are multifactorial, but include genetic effects that contribute to CaP-associated health disparity. We previously showed that in androgen-dependent CaP cells, the androgen receptor (AR) suppresses levels of the receptor tyrosine kinase ErbB3, a molecule that is known to drive CaP progression, by stimulating the E3 ubiquitin ligase Nrdp1 (also called RNF41 or FLRF). The purpose of the current study was to investigate the role of the AR-Nrdp1-ErbB3 signaling axis in CaP development and progression in AA vs CA men with CaP. Methods: All data were collected with approval from the University of California Davis (UCD) or VA Northern California Health Care System (VANCHCS) Institutional Review Board (IRB). Sections from prostate tumors of 157 patients who underwent radical retropubic prostatectomy at UCD (79) or VANCHCS (78) were analyzed for these studies. Tumor and nontumor areas were identified by a pathologist and 60-µm core samples were extracted from the specific areas of the donor blocks. The specimens were arranged in triplicate in a tissue microarray (TMA) using a Beecher Instruments Manual Tissue Arrayer. Hematoxylin-eosin staining was used as a reference for interpreting the additional sections of the TMA stained with antibodies to Nrdp1 and AR. Results: Nrdp1 has two major proteins isoforms of 317 amino acids (36kDa) and 246 amino acids (28kDa)--both isoforms are expressed in CaP. Subcellular fractionation and immunofluorescence staining of various CaP cell lines showed that while the 36 kDa Nrdp1 was localized to both the cytoplasm and the nucleus, the 28 kDa was localized exclusively in the cytoplasm. Hence, we investigated the expression of Nrdp1 in primary prostate tissues from 157 individual patients, including 19 AA, 121 non-Hispanic CA, 5 Hispanic CA, and 11 others. Using a scoring system based on immunohistochemistry (IHC) scores from 0 to 3, where 0 represents no staining and 3 represents 100% staining, we observed that Nrdp1 was strongly expressed in the epithelial cells of the prostate and could be observed in both the nucleus and the cytoplasm. Comparison of cytoplasmic Nrdp1 levels showed no difference in expression between the different racial groups; however, nuclear Nrdp1 levels differed significantly between races (P = 0.008), with post-hoc testing showing significantly higher expression in CA patients than in AA patients (P = 0.002). Therefore, it is likely that the difference is in the 36-kDa fragment and not the 28-kDa fragment. Further, increased preoperative PSA is associated with significantly higher nuclear Nrdp1 levels (P = 0.030), with a Spearman correlation of 0.19. Finally, we demonstrated that","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132210394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A82: Disparities in prostate cancer incidence, patient and clinical characteristics among Latino subpopulations defined by country of origin in California: Findings from the California Cancer Registry","authors":"Alexis R Freedland, Andre E Kim, Juanjuan Zhang, A. Hamilton, D. Deapen, Lihua Liu, I. Gill, M. Stern","doi":"10.1158/1538-7755.DISP17-A82","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-A82","url":null,"abstract":"Introduction and Objective: Latinos constitute a significantly heterogeneous population with unique national identities, sociodemographic characteristics, and ancestry. The prostate cancer (PC) incidence patterns and clinical characteristics are poorly characterized among U.S. Latinos. This gap of knowledge hinders adequate risk-stratification strategies. Particularly lacking are studies that consider Latino subpopulations defined by country of origin. We investigated sociodemographic and clinical characteristics and outcomes of 321,433 men diagnosed with PC in California from 1988-2012, accounting for ethnicity and country of origin using data from the California Cancer Registry. Materials and Methods: Latino status and country of origin were identified by the NAACCR Hispanic Identification. We grouped Latinos (15.9% of all cases) into the following origins: Mexico (MEX, 26.3%), Central/South America (CSA, 6.9%), Cuba (1.3%), Puerto Rico (PR, 0.8%), and unspecified (64.6%). Non-Latino white (NLW, 73.4%) and non-Latino Blacks (NLB, 10.4%) were used for comparison. Nativity (U.S.-born versus foreign-born Latinos) was defined based on birthplace information available in the cancer registry records. SES was based on the geocoding of the participants9 residential address at diagnosis at the census block group level, using a well-established methodology. Annual age-adjusted incidence rates (AAIRs) were calculated. Pearson9s Chi-square was used to test differences among ethnicities and subgroups. Logistic regression was used to test the relationship between changes in Gleason score from biopsy to surgery among all ethnicities and subgroups. Results: Among known LAT subpopulations, Mexicans had the lowest AAIR (44 per 100,000) and Central/South American LAT had the highest (90 per 100,000), followed by Cubans (85 per 100,000) and Puerto Ricans (52 per 100,000). Latinos had a slightly higher proportion of younger diagnoses than NLW, with central/south Americans having the greatest proportion. LAT were more likely to have lower SES than NLW, and more likely to be uninsured. NLB were more likely to have elevated PSA (94.2%) vs NLW (89.0%) and LAT (91.8%, p Conclusion: We observed differences in PC incidence patterns and patient and clinical characteristics among Latino men in California. This highlights the importance of considering the heterogeneity in this minority population in understanding the cancer determinants and patterns of care for PC among Latinos. Citation Format: Alexis R. Freedland, Andre E. Kim, Juanjuan Zhang, Ann Hamilton, Dennis Deapen, Lihua Liu, Inderbir S. Gill, Mariana C. Stern. Disparities in prostate cancer incidence, patient and clinical characteristics among Latino subpopulations defined by country of origin in California: Findings from the California Cancer Registry [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 ","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"82 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132791033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A69: Racial disparity in breast cancer hospital treatment costs: Examining the effect of depression","authors":"B. Husaini, Oscar Miller, Jessica D. Jones, R. Levine","doi":"10.1158/1538-7755.DISP17-A69","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-A69","url":null,"abstract":"Objective: The effect of depression on hospital costs for breast cancer (BC) patients by race remains unknown. This presentation examines two issues by race: (i) hospitalized prevalence of BC and depression among discharged patients, and (ii) racial variation regarding the effect of depression on hospital costs of BC patients. Methods: For BC, available 2008 Tennessee Hospital Discharge Data System (HDDS) was examined. The BC sample (n=2,522) was mostly white (86%) with an average age of 63 years. We computed age-adjusted BC rates per CDC methodology, and determined racial disparity. We compared the hospital costs for BC patients with depression (BC+D) vs. without depression (BCND). Results: Age-adjusted BC rates (per 100K) were higher among white than black patients (43.3 vs. 9.2, p Conclusion: BC prevalence rate is higher among white females compared to black females. Depression increases hospital costs for both white and black patients. Since depression increased cost for both racial groups of patients, considerable cost savings might be attained by screening and treating depression among BC patients before their hospitalization. Citation Format: Baqar Husaini, Oscar Miller, Jessica Jones, Robert Levine. Racial disparity in breast cancer hospital treatment costs: Examining the effect of depression [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr A69.","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"5 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114131417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A72: [Advocate Abstract:] Community initiatives for all women's health","authors":"A. Lucio","doi":"10.1158/1538-7755.DISP17-A72","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-A72","url":null,"abstract":"My poster will describe four community programs I have established at The Resurrection Project. The first focuses on breast cancer education workshops to address the lack of knowledge, cultural misconceptions, fear, and shame in my community and other underserved communities. The second focuses on breast cancer navigation to address the lack of insurance and cost issues in my community and in other underserved communities. The third focuses on breast cancer survivorship and empowerment to address the need for peer role models in my community and for other underserved communities. The fourth focuses on policy advocacy to address the need for resources for other underserved women. Citation Format: Araceli Lucio. [Advocate Abstract:] Community initiatives for all women9s health [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr A72.","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116222734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract B87: [Advocate Abstract:] Prostate cancer survivorship among African American males","authors":"E. Bowen","doi":"10.1158/1538-7755.DISP17-B87","DOIUrl":"https://doi.org/10.1158/1538-7755.DISP17-B87","url":null,"abstract":"African American survivors of prostate cancer and their families share common experiences yet express their reactions in widely divergent ways. Understanding what factors account for those differences helps explain why some survivors have coped extremely well after treatment and why others have struggled. This research is focused on what enabled victims to become successful survivors and its potential impact on subsequent generations. This study sheds new light on the coping and adaptation of survivors and their families from their own perspective. The study was conducted to describe the lived experiences of African American survivors of prostate cancer, to understand the phenomena in their own terms, to provide a description of their experiences with prostate cancer, and to identify interventions that are ethnically and culturally sensitive. The researcher administered a 49-question sociodemographic survey and conducted 25 in-depth interviews, which entailed descriptions of significant events that influenced the recovery process, perceptions of the health care delivery process and health care providers, and specific recommendations for program development and community outreach in African American communities. Citation Format: Earl Bowen. [Advocate Abstract:] Prostate cancer survivorship among African American males [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B87.","PeriodicalId":439465,"journal":{"name":"Organ Site Research","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124447657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}